Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Experimental models to unravel the molecular pathogenesis, cell of origin and stem cell properties of cholangiocarcinoma
Silvestre Vicent, Ruby Lieshout, Anna Saborowski, et al.
Liver International (2019) Vol. 39, Iss. S1, pp. 79-97
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesús M. Bañales, José J.G. Marı́n, Ángela Lamarca, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 9, pp. 557-588
Open Access | Times Cited: 1722
Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma
Chiara Raggi, Maria Letizia Taddei, Elena Sacco, et al.
Journal of Hepatology (2021) Vol. 74, Iss. 6, pp. 1373-1385
Open Access | Times Cited: 106
Digestive cancers: mechanisms, therapeutics and management
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Mitochondrial Fusion Via OPA1 and MFN1 Supports Liver Tumor Cell Metabolism and Growth
Meng Li, Ling Wang, Yijin Wang, et al.
Cells (2020) Vol. 9, Iss. 1, pp. 121-121
Open Access | Times Cited: 96
Autophagy Regulation on Cancer Stem Cell Maintenance, Metastasis, and Therapy Resistance
Xin Wang, Jihye Lee, Changqing Xie
Cancers (2022) Vol. 14, Iss. 2, pp. 381-381
Open Access | Times Cited: 32
Functions and the Emerging Role of the Foetal Liver into Regenerative Medicine
Aldo Giancotti, Marco Monti, L. Nevi, et al.
Cells (2019) Vol. 8, Iss. 8, pp. 914-914
Open Access | Times Cited: 48
Liver Organoids as an In Vitro Model to Study Primary Liver Cancer
Silvia De Siervi, Cristian Turato
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4529-4529
Open Access | Times Cited: 16
From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players
Avilene Rodríguez‐Lara, Ascensión Rueda‐Robles, María José Sáez‐Lara, et al.
Pathogens (2023) Vol. 12, Iss. 7, pp. 940-940
Open Access | Times Cited: 13
Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression
Alphonse E. Sirica, Mario Strazzabosco, Massimiliano Cadamuro
Advances in cancer research (2020), pp. 321-387
Open Access | Times Cited: 36
Somatic mutation landscape reveals differential variability of cell-of-origin for primary liver cancer
Kyungsik Ha, Masashi Fujita, Rosa Karlić, et al.
Heliyon (2020) Vol. 6, Iss. 2, pp. e03350-e03350
Open Access | Times Cited: 33
Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer
Jianzhen Lin, Xinxin Peng, Kun Dong, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 28
Recreating Tumour Complexity in a Dish: Organoid Models to Study Liver Cancer Cells and their Extracellular Environment
van Tienderen, Bas Groot Koerkamp, IJzermans, et al.
Cancers (2019) Vol. 11, Iss. 11, pp. 1706-1706
Open Access | Times Cited: 35
Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models
Qingfan Zheng, Bin Zhang, Changfeng Li, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 18
Environmental and Metabolic Risk Factors Linked to Gallbladder Dysplasia
Andrei Bojan, Cătălin Pricop, Manuela Ciocoiu, et al.
Metabolites (2024) Vol. 14, Iss. 5, pp. 273-273
Open Access | Times Cited: 3
The protease‐inhibitor SerpinB3 as a critical modulator of the stem‐like subset in human cholangiocarcinoma
Margherita Correnti, A. Cappon, Mirella Pastore, et al.
Liver International (2021) Vol. 42, Iss. 1, pp. 233-248
Open Access | Times Cited: 21
Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy
Marianeve Carotenuto, Alessandra Sacco, Laura Forgione, et al.
Exploration of Targeted Anti-tumor Therapy (2022), pp. 200-223
Open Access | Times Cited: 15
Locoregional Approaches in Cholangiocarcinoma Treatment
Alexander E. Hare, Mina S. Makary
Cancers (2022) Vol. 14, Iss. 23, pp. 5853-5853
Open Access | Times Cited: 12
3D Silk Fibroin-Gelatin/Hyaluronic Acid/Heparan Sulfate Scaffold Enhances Expression of Stemness and EMT Markers in Cholangiocarcinoma
Onanong Buhome, Molin Wongwattanakul, Jureerut Daduang, et al.
In Vivo (2022) Vol. 36, Iss. 3, pp. 1155-1167
Open Access | Times Cited: 11
Lymphotoxin beta‐activated LTBR/NIK/RELB axis drives proliferation in cholangiocarcinoma
Kaiyu Xu, Annika Kessler, Federico Nichetti, et al.
Liver International (2024) Vol. 44, Iss. 11, pp. 2950-2963
Open Access | Times Cited: 2
Selecting an Appropriate Experimental Animal Model for Cholangiocarcinoma Research
Man Li, Xueli Zhou, Wei Wang, et al.
Journal of Clinical and Translational Hepatology (2022) Vol. 10, Iss. 4, pp. 700-710
Open Access | Times Cited: 9
Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy
Leonardo Baiocchi, Keisaku Sato, Burcin Ekser, et al.
Expert Opinion on Investigational Drugs (2020) Vol. 30, Iss. 4, pp. 365-375
Open Access | Times Cited: 14
Cellular Origins and Lineage Plasticity in Cancer
Jason R. Pitarresi, Ben Z. Stanger
Cold Spring Harbor Perspectives in Medicine (2023) Vol. 14, Iss. 6, pp. a041389-a041389
Closed Access | Times Cited: 4
Role of noninvasive imaging in the evaluation of intrahepatic cholangiocarcinoma: from diagnosis and prognosis to treatment response
Qian Li, Feng Che, Yi Wei, et al.
Expert Review of Gastroenterology & Hepatology (2021) Vol. 15, Iss. 11, pp. 1267-1279
Closed Access | Times Cited: 9
Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma
Brinda Balasubramanian, Simran Venkatraman, Kyaw Zwar Myint, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 1, pp. 51-51
Open Access | Times Cited: 8
TGFβ-induced circLTBP2 predicts a poor prognosis in intrahepatic cholangiocarcinoma and mediates gemcitabine resistance by sponging miR-338-3p
Corentin Louis, Tanguy Ferlier, Raffaële Leroux, et al.
JHEP Reports (2023) Vol. 5, Iss. 12, pp. 100900-100900
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top